Detection of Varicella-Zoster virus (VZV) DNA in plasma can facilitate the early recognition of complicated VZV-infection in immunocompromised hosts. The correlation of VZV-DNA in plasma with clinical presentations of VZV-infection and subsequent aciclovir treatment in allogeneic stem cell transplant (allo-SCT) recipients was studied. In 81 consecutive VZV-IgG positive allo-SCT recipients, VZV-DNA was measured at regular time points (1, 2 and 4 months) following allo-SCT and patient records were screened for VZV-related symptoms and aciclovir treatment. Subsequently, possible VZV-cases were studied in detail for the course of VZV-DNA and treatment effects. During the initial screening, VZV-DNA was detectable in seven patients. The survey of VZVrelated symptoms revealed five additional possible VZVcases. In cases where suitable plasma samples were available (10 out of 12), VZV-DNA was present almost simultaneously with the first clinical manifestations. No evidence of a preceding phase detectable by VZV-DNA only could be observed. Treatment with aciclovir was associated with a prompt reduction of VZV-DNA load. Detection of VZV-DNA in plasma in allo-SCT recipients accurately reflected the clinical presentation of VZVinfection and treatment with aciclovir. VZV-DNA detection in plasma of allo-SCT recipients appears clinically relevant as this may support early recognition and therapeutic management of VZV-infections following allo-SCT.
Introduction
Varicella-zoster virus (VZV), one of the eight human herpes viruses, is frequently encountered in infections in immunocompromised patients, especially in HIV-infected patients and transplant recipients. Primary infection results in varicella (chickenpox), an extremely contagious acute infection that is characterized by generalized vesicular rash. Reactivation of latent VZV results in dermatomal zoster or visceral zoster, or combinations of these two, while dissemination comparable to primary infections may also occur in immunocompromised patients. 1, 2 Commonly reported complications of disseminated VZV infections in severely immunocompromised patients, such as stem cell transplant (SCT) recipients, include pneumonia, encephalitis and hepatitis. 1 Another serious manifestation of herpes zoster in the immunocompromised host is 'abdominal zoster' characterized by severe abdominal pain that may precede the appearance of the cutaneous rash by hours to days. 1 In allogeneic bone-marrow transplant recipients, VZV reactivation occurs in 20-50% of the cases within the first year after transplantation and prompt therapy with antiviral agents can reduce the risk of dissemination or postherpetic neuralgia. [2] [3] [4] Still, approximately 15% of these cases subsequently develop cutaneous dissemination and 5% develop visceral dissemination. 2, 5 Typically, VZV reactivation occurs between 2 and 6 months after allogeneic BMT, with the majority of the cases occurring within the first year of transplantation. 2, 4 However, reactivation may occur for up to 2 years following transplantation. 4 For therapy of VZV infection or reactivation after SCT, the use of intravenous aciclovir or oral valaciclovir is the treatment of choice. VZV reactivation can be prevented in patients after SCT using oral aciclovir, but only during the period of administration. Hence, such prophylactic use of aciclovir was demonstrated to delay the onset of infection, but not to reduce the overall incidence of VZV reactivation. 4 Furthermore, long-term antiviral prophylaxis also carries the potential for the induction of VZV resistance and manifestation of side effects. 5, 6 Recent advances in molecular techniques have enabled quantification of VZV-DNA in plasma or peripheral blood mononuclear cells (PBMCs) of patients with VZV-related disease. It was shown that VZV-DNA is detectable in peripheral blood of patients with varicella as well as herpes zoster. [7] [8] [9] [10] Therefore, this assay could be of potential value to monitor SCT recipients, with regard to the early recognition and rapid confirmation of VZV-related disease, the proper recognition of atypical presentations including visceral zoster and as a sensitive tool to evaluate the effect of therapeutic interventions.
This study evaluated the use of VZV-DNA detection in plasma in a cohort of 81 consecutive SCT recipients, employing an internally controlled quantitative PCR method. The results obtained by a prospective screening and further retrospective detailed analysis of positive cases should provide insight into the incidence of VZV reactivation, the relation to clinical problems and the effects of treatment on the VZV-DNA load.
Patients and methods

Patients and procedures
Between January 2003 and December 2004, 85 consecutive patients received allogeneic stem cell transplant at the Leiden University Medical Center using a HLA identical sibling, haploid sibling or unrelated donor. Four of these patients were excluded from this study; three were not at risk for VZV reactivation (both donor and recipient were VZV seronegative before transplantation) and no plasma samples were available from one patient. The median age was 50.0 years (range 21-66 years). Data regarding pretransplant serology for VZV, aciclovir treatment and clinical symptoms of VZV-related disease were retrospectively collected from the medical records (treatment charts, diagnosis codes and all correspondence) of the included patients. The main clinical characteristics of the patients are shown in Table 1 .
Two main categories of conditioning regimen were used. Forty-six patients were transplanted with T-cell depleted peripheral blood stem cells following conditioning with a myeloablative regimen as described before. 11 Patients with a relative contraindication for conventional myeloablative allo-SCT (n ¼ 35) received a T-cell depleted allo-SCT following reduced intensity conditioning as described previously. 12 All patients received prophylaxis with cotrimoxazole against Pneumocystis jerovici infections. Surveillance for CMV reactivation was performed by quantitative PCR, and pre-emptive therapy was commenced according to procedures described previously. 13 No graft-versus-host disease prophylaxis was administered.
General institutional policy with respect to patients' informed consent for inclusion into the study, approved by the ethical institutional board, was applied.
VZV-DNAemia and VZV reactivation A two-step approach was pursued to determine the relevance of VZV-DNAemia in this study. Initially, the presence of VZV-DNA in plasma was determined longitudinally in all included patients at 1, 2 and 4 months following transplantation. Patients with at least one positive plasma sample were considered possible VZVcases. Secondly, patients' records were surveyed and patients with compatible clinical problems or aciclovir treatment, potentially associated with VZV within 4 months following transplantation were also referred to as possible VZV-cases. Subsequently, in all possible VZVcases all available plasma samples within 4 month following transplantation, or until death occurred, were used to describe the course of VZV-DNA in more detail.
Diagnosis of VZV infection was based on clinical presentation, considered typical by the responsible physicians (typical rash, dermatomal distribution, fever, pain, itching), and viral culture of tissue from vesicular skin lesions, was additionally included in equivocal cases only. Herpes zoster was treated with intravenous 10 mg/kg aciclovir three times daily for at least 5 days. Positive VZV-DNA load was defined as the presence of more than 250 copies/ml plasma.
Quantification of VZV-DNA in plasma Plasma samples were collected and stored at À201C until the PCR assay was performed. DNA for VZV real-time PCR analysis was isolated from 200 ml serum using the MagNa Pure LC Total Nucleic Acid Isolation Kit (Roche Molecular Diagnostics, Penzberg, Germany). Amplification and quantitative detection of VZV-DNA was performed on a BioRad i-cycler IQt real-time PCR detection system (BioRad, Veenendaal, The Netherlands). Primers (sense: 5 0 -CTCGCC- CGTCTCTATCTC-3 0 , antisense: 5 0 -GATGAGGTGGTT-GTTATTGTTC-3 0 ) and probe (FAM5 0 CGCGATCGAC-GAAGCGTGCCAG-TTGAATCGCG-3 0 DABCYL) were selected to detect a 139 bp fragment from the glycoprotein gene (ORF 31) of the VZV genome. The sensitivity and the specificity of the real-time VZV-DNA PCR were evaluated. In order to quantify the VZV-DNA in clinical samples, log 10 dilutions of the QCMD standard for VZV-DNA starting at 5.10e5 IU/ml were tested and used as an external standard curve.
Co-amplification of Phocine herpesvirus (PhHV), spiked to each sample before DNA extraction, was used as an internal control to check for the DNA isolation and inhibition in the PCR as described previously. 13 The VZV real-time PCR assay has been used in our laboratory as a routine diagnostic assay for swabs for 3 years. The assay was validated in comparison to the previously used conventional PCR. Quality control is performed by monitoring C t -values of positive controls in time and by participating in the QCMD proficiency panels. In the QCMD 2005 panel a 100% score was achieved. This panel contained a sample (VZV05-07) with 260 GEq/ml, which is 5 GEq in the PCR.
VZV IgG detection
Pre-transplant VZV-IgG antibody titres were routinely performed for all transplant recipients using the ELFA VZV-IgG assay (Biomerieux, Boxtel, The Netherlands) according to the manufacturer's instructions. Patients with pre-transplant negative VZV-IgG test values were not considered at risk for VZV-disease following transplantation and were excluded from this study. Additionally, in patients with VZV-disease, VZV-IgG antibody values were determined at the end of the episodes and at 4-month following transplantation. No prophylaxis with immunoglobulin, acyclovir or ganciclovir was administered.
Statistical analysis
All database entries and statistical analysis were performed with SPSS version 12.0.1. For comparison of noncategorical data we used Mann-Whitney U-test.
Results
Detection of possible VZV-cases after initial screening
In total, 81 patients with positive pre-transplant VZV-IgG antibody titres were included as they were considered to be at risk for VZV disease following transplant. Twelve out of these 81 transplant recipients (15%) were considered possible VZV-cases. In seven of these cases, VZV-DNA was detectable in at least one plasma sample during the regular screening at 1, 2 and 4 months following transplantation (Figure 1a-g ). A survey of clinical problems potentially associated with VZV infection revealed five additional possible VZV-cases, not detected in the initial screening; three of which are represented by Figure 1h -j.
The course of VZV-DNA was analyzed in more detail in 10 possible VZV-cases; in the remaining two possible VZVcases, no plasma samples were available during the VZV disease episodes. Median time to the first detectable VZV-DNA load in plasma following transplantation was 36 days (range; 14-83 days), and the median peak load was 3.85 log 10 copies/ml plasma (range: 2.6 log 10 -5.3 log 10 ). The median time to reach the peak load was not different from the median time to the first detectable load (36 days) as in most cases the initial load was also the peak load.
Correlation of VZV-DNA in plasma with clinical course of VZV-related disease Correlation with clinical data revealed that all seven possible VZV-cases from the initial VZV-DNA screening presented with herpes zoster-like skin lesions and were treated with aciclovir at time of detectable VZV-DNA in plasma (Figure 1a-g ). In five out of these seven cases (Figure 1a-e) , diagnosis of VZV infections was based on typical clinical presentation and in the two remaining cases (Figure 1f and g ), confirmation using viral culture were considered necessary. However, viral cultures could provide confirmation in only one case (Figure 1f ). The patient represented by Figure 1d showed progression to disseminated disease and bilateral progressive retinal necrosis. 14 In five possible VZV-cases from the clinical data survey, diagnoses of VZV infections were based on typical clinical presentation. Confirmation by viral culture was considered necessary in three out of these five cases (Figure 1h-j) and could only be provided in one case (Figure 1i ). In three out of five possible VZV-cases from the clinical data survey, from whom plasma samples were available, VZV-DNA was detectable at time of herpes-zoster skin lesions (Figure 1h-j) .
In total, 12 out of 80 transplanted patients presented with herpes-zoster skin lesions within 4 months after transplantation. The sensitivity and specificity of regular screening (at 1, 2 and 4 months following transplant) for VZV DNA for actual VZV disease was 58 and 100%, respectively (Table 2 ). Viral culture was considered necessary for the confirmation of the diagnosis of VZV infection in five out of 12 cases and this confirmation could only be provided in two cases. No clear associations were observed between the occurrence of VZV infection and conditioning regimen (VZV infection occurred in four out of 35 (11.4%) and eight out of 46 (17.4%) patients receiving reduced intensity and myeloablative conditioning, respectively) or donor type (VZV infection was observed in nine out 59 (15.3%) and in three out of 22 (13.6) patients receiving grafts from related donors and unrelated donors, respectively). If suitable specimens were available (as in 10 of these 12 patients), no VZV-related clinical conditions were observed without simultaneous VZV-DNA detection in plasma and conversely, all VZV-DNA positive cases concurrently presented with VZV-related disease. Furthermore, VZV-DNA was detectable in plasma in cases where viral culture could not confirm the diagnosis of VZV infection (Figure 1g, h and j) . VZV-DNA in plasma was present almost simultaneously with the first clinical manifestation and no evidence of preceding phase of positive VZV-DNA could be observed. Except for the VZV retinitis case (Figure 1d ), no other atypical cases or visceral zoster cases were detected in this cohort.
Effect of aciclovir treatment on the course of VZV-DNA load in plasma Treatment with aciclovir resulted in a rapid resolution of herpes zoster skin lesions in all patients. This clinical response to aciclovir treatment was consequently reflected by a prompt decrease of VZV-DNA load upon treatment with aciclovir in all cases where suitable plasma samples were available (Figure 1a-j) . respectively. The analysis of VZV-IgG titres following transplantation was limited to the 10 patients clinically positive for VZV disease and VZV DNA in plasma, since no effect on VZV-IgG titres were seen in relation to VZV disease.
Discussion
This study was performed to evaluate the use of VZV-DNA detection in plasma from SCT recipients. Initially, VZV-DNA was measured at regular time points and patient records were screened for VZV-related clinical problems. Subsequently, positive cases resulting from both these approaches were analyzed in more detail. Twelve patients with VZV-disease, occurring within 4 months following transplantation were recognized. It should be noted that the incidence of 12 cases with VZV infection within 4 months following allo-SCT is a minimal estimate, since possible interference with CMV therapy by ganciclovir in this group cannot be excluded. In this respect, the study was designed to evaluate the use of VZV-DNA detection in plasma following allo-SCT, rather then to perform a systematic epidemiological survey. It appeared that the timing of VZV-DNA detection as used in this study was not able to uncover all clinical cases of VZV-disease, as in five out of 12 VZV-cases, no VZV DNA was detected in plasma at 1, 2 and 4 months following transplant. However, in all cases with VZV-related clinical symptoms, concomitant VZV-DNA detection in plasma was observed, if suitable specimens were available. Furthermore, all VZV-DNA positive cases concurrently presented with VZV-like disease and treatment resulted in prompt reductions of VZV-DNA as clinical symptoms resolved. Attempts to confirm a clinical diagnosis by viral culture remarkably were largely unsuccessful, probably due to the relative low sensitivity of this procedure in routine clinical practice. These findings are indicative of a high sensitivity and specificity of VZV-DNA detection in plasma following allo-SCT, and are in agreement with a previous report. 5 Analysis of the course of VZV-IgG antibody values clearly demonstrated no effect of VZV-IgG titres in relation to VZV disease and VZV DNA detection in this group of patients who are apparently incapable of mounting an adequate humoral immune response against VZV within 4 months following allo-SCT.
It has previously been reported that severe complications of disseminated zoster infections appear to be associated with elevated VZV-DNA levels in sequential plasma specimen, 8, 9, 15 enabling early diagnosis and treatment of these severe manifestations of VZV infections. In the current study, all 12 VZV-cases presented with cutaneous lesions and except for one patient presenting with unusual involvement of the eyes, as described previously in more details, 14 no severe complications of VZV infection were detected. By determining VZV-DNA at time points as used in this study no evidence of a preceding phase of positive VZV-DNA could be observed in these patients with uncomplicated cutaneous VZV-disease. As a consequence, any attempt to design pre-emptive policies to prevent VZV disease, as have been described for CMV and EBV, will encounter severe limitations because of the nearly coincidental rise in VZV DNA and clinical symptoms. If still a pre-emptive approach would be pursued, more intensive sampling (e.g. one or twice a week) might be required.
In conclusion, this study demonstrated that the use of VZV-DNA detection in plasma could be useful in the diagnosis of VZV-related disease in SCT recipients, allowing an early and specific confirmation of clinical suspicion and reflecting accurately the clinical course, including the effects of treatment. The potential benefit of regular screening, enabling pre-emptive therapeutic strategies with regard to VZV diseases, could not be demonstrated in the present study and would therefore at least require more intensive sampling. The calculated sensitivity and specificity of VZV-DNA detection for actual VZV disease were 58 and 100%, respectively (positive predictive value: 100%; negative predictive value: 93%).
